Rorer offering
Executive Summary
Firm filed registration covering a public offering of 4.9 mil. common shares, and an equal number of share purchase rights. The shares are issuable upon conversion and/or redemption of the $250 mil. principal amount of 6% senior subordinated debentures issued by the company on Oct. 1. Shares are valued at $51.25 each. Company said a portion of the net proceeds from the sale of the debentures has been used, and the remaining proceeds will be used to repay some of the debt incurred with the USV/Armour acquisition.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.